Key Highlights
- Cellectis (NASDAQ: CLLS) shares fell 41% after announcing a strategic pivot toward in vivo gene-editing programs.
- PDS Biotechnology (NASDAQ: PDSB) shares rose 35% after completing an $11.3 million PIPE financing.
- Tyra Biosciences (NASDAQ: TYRA) shares rose 14% after pricing a $400 million public offering.
- Contineum Therapeutics (NASDAQ: CTNM) reported that its Johnson & Johnson-partnered depression asset missed its primary endpoint.
A separate cluster of biotech names moved on financing actions, corporate restructuring, and one clinical trial miss, spanning gene editing, cancer immunotherapy, industrial biotech, oncology, Long COVID, and depression.
Cellectis (NASDAQ: CLLS): Pivot to In Vivo Gene Editing
Cellectis shares closed down 41% at $1.83 after the company announced a strategic pivot toward in vivo gene-editing programs, focusing resources on HEAL-101 for APOC3 in severe hypertriglyceridemia and HEAL-201 for PCSK9 in severe hypercholesterolemia. Initial Phase 1 readouts are expected in the second half of 2027 and first half of 2028, respectively, while the company is discontinuing clinical work on lasme-cel and eti-cel to stretch its operational cash runway into the second half of 2028.
PDS Biotechnology (NASDAQ: PDSB): $11.3 Million PIPE Financing
PDS Biotechnology shares closed up 35% at $0.40 after completing the initial closing of an approximately $11.3 million PIPE led by Nant Capital, with a further $11.0 million milestone closing tied to submission of a registrational Phase 3 PDS0301 protocol to the FDA. The Capital will help repay Debt and support late-stage development, while NantWorks receives a one-year exclusive negotiation right for PDS0101 and Dr. Patrick Soon-Shiong joins the board.
Dyadic International (NASDAQ: DYAI): Resale Prospectus Filed
Dyadic International shares closed down 13% at $0.42 after the company submitted a resale prospectus registering up to 3.625 million shares for selling stockholders. The filing generates no direct proceeds for the firm while establishing potential market overhang following its recent registered direct offering at $0.795 per share.
Tyra Biosciences (NASDAQ: TYRA): $400 Million Public Offering
Tyra Biosciences shares closed up 14% at $25.07 after announcing the pricing of a $400 million underwritten public offering featuring common stock alongside pre-funded warrants at $22.03 per share equivalent, led by RA Capital alongside broad institutional backing. The capital is intended to progress the company's dabogratinib 3x3 pipeline across LG-UTUC, IR NMIBC, and achondroplasia indications, while funding preclinical research and general operational needs.
BioVie (NASDAQ: BIVI): ATM Offering Ahead of Long COVID Readout
BioVie shares closed up 6% at $2.05 after the company entered into an at-the-market offering agreement with A.G.P. to issue and sell up to $6.46 million of Class A common stock for Working Capital and general corporate needs. The financing provides additional funding capacity while introducing possible share dilution ahead of the anticipated September 15 Phase 2 ADDRESS-LC trial readout evaluating bezisterim for Long COVID.
Contineum Therapeutics (NASDAQ: CTNM): Phase 2 Depression Trial Misses Endpoint
Contineum Therapeutics reported that its Johnson & Johnson-partnered asset, JNJ-5120/PIPE-307, missed its primary endpoint in the Phase 2 MOONLIGHT-1 major depressive disorder study, failing to show a statistically significant MADRS total score reduction against placebo at Day 5. The compound was well tolerated, with zero novel safety concerns, as exploratory evaluation continues to guide future development.


_11_17_2026_13_39_08_971706.jpg)



Please wait processing your request...